GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 89bio Inc (NAS:ETNB) » Definitions » Cash per Share

89bio (ETNB) Cash per Share : $5.91 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is 89bio Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). 89bio's Cash per Share for the quarter that ended in Mar. 2024 was $5.91.

89bio Cash per Share Historical Data

The historical data trend for 89bio's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

89bio Cash per Share Chart

89bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial 6.77 10.27 7.42 3.72 6.21

89bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.60 6.33 5.93 6.21 5.91

89bio Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

89bio's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=578.87/93.27
=6.21

89bio's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=562.288/95.20
=5.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

89bio  (NAS:ETNB) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

89bio Cash per Share Related Terms

Thank you for viewing the detailed overview of 89bio's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

89bio (ETNB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 89bio Inc (NAS:ETNB) » Definitions » Cash per Share
Comparable Companies
WVE OABI HLVX EDIT BCYC CABA TRDA PHAT TVTX ARCT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104
Website
https://www.89bio.com
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Executives
Kathleen Laporte director
Rohan Palekar director, officer: Chief Executive Officer 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Atkinson Edward Morrow Iii director C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Quoc Le-nguyen officer: See Remarks 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Ryan Martins officer: Chief Financial Officer 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Michael R Hayden director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ram Waisbourd officer: See Remarks 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Gregory Grunberg director, 10 percent owner 100 BEAVER STREET, WALTHAM MA 02453
Anat Naschitz director, 10 percent owner 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026